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ABSTRACT: Breast cancer is one of the leading causes of cancer
death in women. Novel in vitro tools that integrate three-dimensional
(3D) tumor models with highly sensitive chemical reporters can
provide useful information to aid biological characterization of cancer
phenotype and understanding of drug activity. The combination of
surface-enhanced Raman scattering (SERS) techniques with micro-
fluidic technologies offers new opportunities for highly selective,
specific, and multiplexed nanoparticle-based assays. Here, we
explored the use of functionalized nanoparticles for the detection of
estrogen receptor alpha (ERα) expression in a 3D tumor model, using
the ERα-positive human breast cancer cell line MCF-7. This
approach was used to compare targeted versus nontargeted
nanoparticle interactions with the tumor model to better understand
whether targeted nanotags are required to efficiently target ERα.
Mixtures of targeted anti-ERα antibody-functionalized nanotags (ERα-AuNPs) and nontargeted (against ERα) anti-human
epidermal growth factor receptor 2 (HER2) antibody-functionalized nanotags (HER2-AuNPs), with different Raman reporters with
a similar SERS signal intensity, were incubated with MCF-7 spheroids in microfluidic devices and spectroscopically analyzed using
SERS. MCF-7 cells express high levels of ERα and no detectable levels of HER2. 2D and 3D SERS measurements confirmed the
strong targeting effect of ERα-AuNP nanotags to the MCF-7 spheroids in contrast to HER2-AuNPs (63% signal reduction).
Moreover, 3D SERS measurements confirmed the differentiation between the targeted and the nontargeted nanotags. Finally, we
demonstrated how nanotag uptake by MCF-7 spheroids was affected by the drug fulvestrant, the first-in-class approved selective
estrogen receptor degrader (SERD). These results illustrate the potential of using SERS and microfluidics as a powerful in vitro
platform for the characterization of 3D tumor models and the investigation of SERD activity.
Breast cancer is a major health issue among womenworldwide.1,2 In the UK, one person is diagnosed with
breast cancer every 10 min and one in eight women will
develop breast cancer at some point in their lives.3 Various
studies have shown that breast cancer proliferation and
metastasis are highly affected by the cancer cellular and
physical microenvironment.4−6 A limitation of cell-based
studies for breast cancer is that the majority of the
characterization and development of new therapeutic agents
are conducted in two-dimensional (2D) monolayer cell
cultures.7 Therefore, cellular processes, such as drug transport
and cell−cell and/or cell−matrix interactions, are not taken
into consideration.8,9 Studies have shown that 2D breast
cancer cell cultures have different behaviors, gene expression,
and, usually, higher sensitivity to anti-cancer drugs than three-
dimensional (3D) models.10,11 Significantly, many drug
compounds that have been found to be efficient in 2D
cultures have failed in clinical trials.12,13 These findings justify
the need for using 3D in vitro tumor models to better
recapitulate certain aspects of the in vivo breast cancer
microenvironment.
Microfluidic technologies offer a powerful tool for the
creation of 3D cancer models (e.g., spheroids) and in vitro
mechanistic studies.14,15 The technology is an excellent tool to
bridge the gap between 2D monolayer cultures and animal
models, offering cost-effective solutions for miniaturized yet
high throughput assays with high accuracy, faster analysis, and
potential for automation.16−19
Received: January 14, 2021
Accepted: March 22, 2021
Articlepubs.acs.org/ac






























































































Importantly, microfluidics can be combined with analytical
spectroscopic methods, such as fluorescence microscopy20−22
or surface-enhanced Raman spectroscopy (SERS).23 For
instance, the combination of SERS with microfluidic devices
has been applied to rapid analysis of food contaminants,24
multiplex recognition of interleukins from blood plasma,25 and
detection of prostate cancer biomarkers.26 Aberasturi et al.
focused on using microfluidic devices and 3D SERS imaging to
distinguish unlabeled and nanotag-labeled fibroblast cells to
mimic different cell populations within a tissue.27 Moreover,
Altunbek et al. used SERS and the hanging drop method to
monitor the cellular response to drug exposure.28
SERS offers signal enhancement factors of 104−108 in
comparison to conventional Raman by adsorbing a molecule of
interest onto a roughened metal surface, such as colloidal
suspensions of gold and silver nanoparticles.29−31 SERS is a
noninvasive technique, compared to other destructive
analytical methods such as transition electron microscopy
(TEM), that offers high specificity, selectivity, and multiplexed
capabilities due to the sharp fingerprint spectra produced.32,33
Additionally, fluorescence imaging is prone to photobleaching
making 3D imaging exceptionally challenging since bleaching
can compromise the definition of 3D structures leading to false
results. Moreover, fluorescence, in contrast to SERS, generates
a broad emission band making the detection of multiple
components within the same sample challenging in a 3D
structure. Recently, there have been significant developments
in using SERS for cancer imaging34−36 and drug screening.37,38
The enhanced permeability and retention (EPR) effect has
been the main reason behind the high enthusiasm for the
development of nanoparticles in cancer research. The EPR
effect is the mechanism by which nanoparticles passively
accumulate at a tumor sites.39 Although the EPR effect
provides an advantage toward the nanoparticles since they
remain in the tumor site for imaging for relatively long
periods,40 its function can be unpredictable and highly
heterogeneous in preclinical animal models with doubts over
how valid this effect is in humans.41−43 Therefore, active
targeting of nanoparticles, using antibodies and peptides, has
been developed to efficiently target the nanoparticles to the
tumor site.44,45 Antibodies can be used as targeting agents
attached to the nanoparticles since the concentration of certain
proteins expressed in the body can be used as a biomarker of
cell function that indicates the presence of a pathological
condition. The targeted nanoparticles are therefore bound to
the tumor site based on their specific biological activity.40
Studies have shown that the targeted nanoparticles increase the
number of nanomaterials taken up by the tumor cells46 and the
total accumulation at the tumor site, thus minimizing
nonspecific effects.47 Smith et al. have shown that ligand-
targeted nanomaterials accumulated more in tumors and
bound to individual tumor cells than the nonligand targeted
nanomaterials that were cleared during the experimental
time.42
In this study, we developed a novel assay that combines
microfluidic and SERS techniques for tumor identification,
phenotype characterization, and assessment of drug activity in
3D breast cancer spheroids. More importantly, we used
targeted gold nanoparticles (AuNPs) functionalized with
anti-estrogen receptor alpha antibodies (ERα-AuNPs) and
nontargeted (against ERα) nanoparticles functionalized with
anti-human epidermal growth factor antibodies (HER2-
AuNPs) for the characterization of ERα overexpressing
MCF-7 spheroids using SERS. This approach gave us a great
insight into the benefits of using targeted nanotags versus
nontargeted ones in a 3D environment for the characterization
of ERα cancer phenotype. In addition, we investigated the
effects of fulvestrant activity, a commercially available selective
estrogen receptor degrader (SERD). This proof-of-concept
work opens up opportunities for using 3D models, micro-
fluidics, and SERS to investigate in a miniaturized and scalable
manner the drug response of advanced in vitro models to
preclinical compounds.
■ EXPERIMENTAL SECTION
Materials. Anti-estrogen receptor alpha (ERα) antibody
(ab16660) and Anti-Erb2 (HER2) antibody (ab16899) were
purchased from Abcam (330 Cambridge Science Park,
Cambridge, CB4 0FL, UK). Anti-mouse IgG HRP-linked
antibody (7076S) and anti-rabbit IgG HRP-linked antibody
(7074S) were purchased from Cell Signalling Technology
(Hamilton House, Mabledon Place, London, WC1H 9BB,
UK). Sodium tetrachloroaurate dihydrate, (N-(3-dimethylami-
nopropyl)-N′-ethylcarbodiimide hydrochloride) (EDC), N-
hydroxysulfosuccinimide sodium salt (NHS), poly(ethylene
glycol) 2-mercaptoethyl ether acetic acid (HS-PEG5000-
COOH), dynasore hydrate, 1,2-bis(4-pyridyl) ethylene
(BPE), 4-(2-hydroxyethyl)-1-piperazineethancesulfonic acid
(HEPES), 2-(N-morpholino) ethanesulfonic acid (MES),
LIVE/DEAD Viability/Cytotoxicity Assay Kit diacetate
(FDA)-propidium iodide (PI), and Synperonic F108 were
obtained from Sigma-Aldrich Ltd. (The Old Brickyard, New
Road, Gillingham, Dorset, SP8 4XT, UK). The LIVE/DEAD
Viability/Cytotoxicity Assay Kit was purchased from Thermo-
Fisher Scientific (3 Fountain Drive, Inchinnan, Renfrew PA4
9RF, UK). Milli-Q deionized water was used after purification
using a Milli-Q purification system. All glassware was cleaned
in aqua regia (3 HCl:1 HNO3).
Device Design Preparation. Multilayered microfluidic
devices were produced using standard soft lithography
techniques and used for culturing spheroids, following
established protocols. Each device consisted of a microfluidic
channel connected by two open wells. Each channel hosted
four arrays of 64 square microwells (150 × 150 × 150 μm3), as
previously reported.48 Briefly, a 10:1 ratio of the polydime-
thylsiloxane (PDMS) prepolymer (Sylgard 184, Dow Corning)
to the curing agent was mixed and dispensed onto patterned
silicon wafers. The wafers were degassed and subsequently
incubated at 85 °C for a minimum of 3 h to allow curing of the
PDMS solution. PDMS layers were then cut from the wafers,
and open wells were formed using a 4 mm surgical biopsy
punch (Miltex). The PDMS layers were cleaned and treated
with oxygen plasma (Pico plasma cleaner, Diener electronic)
to permanently bond the layers together, forming a micro-
fluidic device. Devices were then stored overnight at 85 °C and
exposed a second time to oxygen plasma before injecting a 1%
solution of Synperonic F108 (Sigma Aldrich), creating ultra-
low-adhesion conditions. Subsequently, devices were washed
using phosphate-buffered saline (PBS) and Roswell Park
Memorial Institute 1640 culture medium (RPMI). Devices
were stored at 37 °C and 5% CO2 in a humidified incubator
prior to cell seeding. Cells were seeded into devices at a
concentration of 5 × 106 cells/mL to form spheroids as
previously reported.48 At least 32 spheroids per conditions
were analyzed. The medium was exchanged every 48 h.
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Nanoparticle Synthesis and Functionalization of ERα-
AuNP and HER2-AuNP Nanotags. Bare AuNPs were
synthesized by standard citrate reduction of gold.49 The
functionalization, characterization, and stability of ERα-AuNPs
SERS nanotags have been previously reported by our group.50
Briefly, anti-ERα antibodies were attached to the AuNP gold
surface via carbodiimide cross-linking chemistry. The coupling
chemistry was achieved after the attachment of the 1,2-bis(4-
pyridyl) ethylene (BPE) Raman reporter to the AuNP surface.
For anti-HER2 functionalization, 10 μL of 4-(1H-pyrazol-4-
yl)pyridine (PPY) (0.1 μM) was added to bare AuNPs (0.03
nM, 990 μL) and the solution was incubated on a shaker plate
for 30 min followed by centrifugation at 6000 rpm for 20 min.
The solution of EDC-NHS-PEG5000-mAb was added
dropwise to the pelleted PPY-AuNPs. The nanotags were
incubated on a shaker plate for 3 h. The free protein was
removed by centrifugation at 6000 rpm for 10 min and was
used for protein estimation analysis. The nanotags did not
demonstrate any aggregation and maintained their strong and
characteristic SERS signals.
Nanoparticle Characterization. Extinction spectra were
measured using an Agilent Cary 60 UV−Visible (UV−vis)
spectrophotometer with Win UV scan V.2.00 software. The
instrument was allowed to equilibrate to RT before using
poly(methyl methacrylate) (PMMA) disposable plastic micro
cuvettes with 500 μL sample volumes to scan wavelengths of
300−800 nm. Where required, samples were diluted to give
extinction values of less than 1 to adhere to the Beer−Lambert
law, to allow calculation of the concentration of AuNPs.
Dynamic light scattering (DLS) and zeta potential were
measured using a Malvern Zetasizer Nano ZS with 800 μL of
the sample in a PMMA disposable microcuvette with Zetasizer
μV and APS v.6.20 software. Polystyrene latex beads (40 nm)
were used as a standard to validate the calibration of the
system before running samples. Measurements were taken in
triplicate. For the solution measurements of the nanotags,
SERS analysis was carried out using a Snowy Range CBEx 2.0
handheld Raman spectrometer (Snowy Range Instruments,
Laramie, WY, USA) equipped with a 638 nm laser with a
maximum laser power of 40 mW. Samples were placed into
glass vials for analysis. The sample volumes were 600 μL, and
spectra were collected using 100% laser power at the sample
with a 0.05 s accumulation time. The software used to acquire
spectra was Peak 1.1.112.
2D Breast Cancer Cell Culture. MCF-7 cells (ATCC
HTB-22) were obtained from American Type Culture
Collection (ATCC) (Queens Road, Teddington, Middlesex,
TW11 0LY, UK). The human breast cancer cells were cultured
in a Rosewell Park Memorial Institute medium (RPMI 1640)
supplemented with 1% penicillin/streptomycin (10,000 units
per mL), 1% fungizone, and 10% heat-inactivated fetal bovine
serum (FBS). Cells were incubated at 37 °C and 5% CO2 in a
humidified incubator. Cells at a confluence of ca. 90% growing
in a T175 flask were trypsinized and resuspended in the RMPI
medium.
Nanotag Loading and Fulvestrant Treatment in
Microfluidic Devices. For the purposes of this study, the
initial stock of fulvestrant was made in DMSO and stored at 4
°C. According to the supplier’s instructions, the solubility of
fulvestrant in water is 9.53 × 10−3 mg/mL while in DMSO it is
20 mg/mL at 25 °C. For the dilution of fulvestrant stock, water
was used to ensure that the residual amount of organic solvent
was insignificant and had no physiological effects on our
models. Immediately prior to injection into devices, fulvestrant
solution was diluted in RPMI media to the desired
concentration. Spheroids were exposed to fulvestrant solution
(1 and 10 μΜ) on the third day of culture in the microfluidic
devices and incubated for 24 h at 37 °C and 5% CO2. This was
followed by the removal of the drug and the addition of
nanotags: ERα-AuNPs (60 pM), HER2-AuNPs (60 pM), or a
mixture of ERα + HER2-AuNPs (60 pM). Nanotags were
gently pipetted up and down prior to injection into devices,
ensuring a flow of the nanotags through the entirety of the
microfluidic channel. After a 2 h incubation period, nanotags
were removed, and the channels were washed twice with PBS
to remove any unbound nanotags. Control experiments were
performed for each set of experiments.
Cell Viability Studies in Microfluidic Devices. To
determine spheroid viability throughout the culture period,
staining of spheroids was performed at several time points:
immediately after nanotag exposure (day 4), 3 days after
nanotag exposure (day 7), and 6 days after nanotag exposure
(day 10). Spheroids were stained with 8 μg/mL fluorescein
diacetate (FDA) and 20 μg/mL propidium iodide (PI). The
staining solution was added to the devices and then incubated
for 30 min. PBS was then used to wash excess staining solution
and was added a second time prior to imaging.
Microscopy and Image Analysis. Spheroids were imaged
via bright-field microscopy using an inverted microscope (Axio
Observer Z1, Zeiss) connected to an Orca Flash 4.0 camera
(Hamamatsu). Images were collected every second day and
before and after drug treatment and nanoparticle exposure.
Image analysis was performed using ZEN Blue, Fiji, and
Matlab to estimate the spheroid area and perimeter. The viable
fraction (Vf), a parameter used to quantify spheroid health,
was calculated for each spheroid as the ratio of FDA stain area
over the bright-field area on the day prior to drug
administration, as previously reported.48 Spheroids possessing
a Vf ≥ 1 were considered to have been unaltered by exposure
to nanotags or fulvestrant treatment since they had either
remained the same size or increased in size over the culture
period. In contrast, spheroids with a Vf < 1 were regarded as
unhealthy or as having been negatively affected due to
administration of the nanotags or fulvestrant. The shape factor
(Sf) of a spheroid, a marker of spheroid disaggregation, was
also used as an assessment of its health, as previously
described.48
SERS Cell Mapping. A Renishaw InVia Raman confocal
microscope (Renishaw, Wolton-under-Edge, U.K.) was used to
generate 2D and 3D SERS data. For SERS mapping, the
microfluidic devices were positioned upside down to allow
scanning under an upright confocal microscope. This process
resulted in the translocation of spheroids toward the corner of
the device microwells without affecting their integrity. 2D
SERS maps were collected using edge Streamline HR high
confocality mode with 3 μm spatial resolution in the x and y
directions. 3D SERS maps were collected using edge
Streamline HR high confocality mode with a 3 μm step size
resolution in the x and y directions and 4 μm between z-stacks.
A 20× objective (0.40 NA) was used on the samples with a
laser power of 12 mW (100% power) at the sample, from a
HeNe 633 nm excitation source with a 0.1 s acquisition time
per point, and a 1200 lines/mm grating in high confocality
mode. A Windows-based Raman Environment (WiRE -
Renishaw plc) 4.4 software package was used to preprocess
the data by using their proprietary nearest neighbor, then
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width of feature cosmic ray removal, and baseline subtraction
features. The image was generated using direct classical least
squares analysis (DCLS) based on a BPE or PPY reference
SERS spectrum whereby a false color was generated only when
there was a good spectral fit between the reference and the
collected spectra.
Statistical Analysis. Statistical analysis was carried out
with GraphPad Prism 8.1.2 (GraphPad Software, Inc., San
Diego, CA). Student’s t-test was used for comparison of two
variables, and one-way analysis of variance (ANOVA) with
post-hoc Tukey’s test was used for comparison of three or
more groups. Differences between groups were considered to
be significant at a P value of <0.05.
■ RESULTS AND DISCUSSION
Synthesis and Characterization of ERα-AuNPs and
HER2-AuNPs. For the nanotag design, anti-ERα (ERα-
AuNPs) or anti-HER2 (HER2-AuNPs) antibodies were
covalently attached to the surface of 50 nm gold nanoparticles
using the EDC-NHS coupling reaction.51 Poly(ethylene
glycol) 2-mercaptoethyl ether acetic acid (HS-PEG5000-
COOH) was added to the nanoparticle surface to avoid
dissociation of the biomolecules, decrease toxic effects, and
help the functionalization process. To confirm the successful
functionalization, the nanotags were characterized using
extinction spectroscopy, agarose electrophoresis, a lateral
flow immunosorbent assay, and dynamic light scattering
(DLS). The extinction spectra showed that there was a shift
in LSPR when antibodies were added to the surface of the
AuNPs (Figure S1A,B), indicating the successful attachment of
the antibody to the metal surface. The nanotags did not
demonstrate any indication of aggregation in the extinction
spectra, suggesting that the AuNPs remained stable after the
addition of the antibodies to their surface. The successful
antibody functionalization was also confirmed with agarose gel
electrophoresis since the PEG-AuNPs traveled further than the
ERα-AuNPs and HER2-AuNPs, suggesting that the nanotags
were of different size and/or charge (Figure S1C). The lateral
flow immunosorbent assay (LFA) also showed that the
antibodies were on the AuNP surface and that they remained
active since a spot was observed on the detection zone of the
nitrocellulose strip when the nanotags bound to their matching
secondary IgG antibodies (anti-rabbit IgG for ERα and anti-
mouse IgG for HER2). There was no spot observed when
control PEG5000-AuNPs were tested with the anti-mouse IgG
and anti-rabbit IgG, confirming the successful binding of the
anti-ERα antibody and anti-HER2 to the AuNP surface
(Figure S1D). Finally, DLS confirmed the successful antibody
functionalization since the hydrodynamic diameter of the
nanotags increased from 73.0 ± 1.0 to 80.3 ± 1.6 nm for ERα-
AuNPs and to 79.8 ± 0.6 nm at pH 7.0 after the
bioconjugation (Figure S1E,F). Therefore, the nanotag
characterization confirmed that the AuNPs were successfully
Figure 1. Effects of the ERα-AuNP and ERα + HER2-AuNP mixture on formation and viability of MCF-7 spheroids. (A) Schematic diagram
showing the principle of formation of MCF-7 spheroids in the low-adhesion microfluidic device. (B) Representative images of spheroid viability at
different time points. Viable cells appeared as green (fluorescein diacetate (FDA) staining), while nonviable cells appear as red (propidium iodide
(PI) staining). (C) Bright-field images showing temporal evolution of MCF-7 spheroids cultured in a microfluidic device over a period of 10 days
with ERα-AuNP and ERα + HER2-AuNP treatment. D1 = day 1 of cell seeding, D4(B) = day 4 of cell seeding (before the addition of nanotags),
D4(A) = day 4 of cell seeding (after the addition of nanotags), D7 = day 7 of cell seeding, D10 = day 10 of cell seeding. (D) Bar plot of the viable
fraction of the untreated spheroids, spheroids treated with ERα-AuNPs, and spheroids treated with the ERα + HER2-AuNP mixture. For the plots,
each point was obtained from 32 spheroids. Error bars presented as mean ± S.D.
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functionalized with ERα and HER2 antibodies that retained
their bioactivities.
Formation of MCF-7 Spheroids and Cell Viability
Studies after Nanotag Incubation. A suspension of ERα
overexpressing MCF-7 cells was injected into microfluidic
devices for spheroid formation. PDMS was used for the
fabrication of microfluidic chips since it is a biocompatible,
transparent polymer with low autofluorescence character-
istics.52,53 Here, cells sedimented at the bottom of the device
microwells, and due to low-adhesion conditions, spheroids
were formed within 48 h of culture, and they were defined
from their spherical and elliptical geometry (Figure 1A). MCF-
7 cells express high levels of ERα and no detectable levels of
HER2 (Figure S2). A Western blot confirmed that the MCF-7
cells used were positive for ERα but did not express any
detectable levels of HER2 (Figure S2). An ERα-AuNP or the
ER-α/HER2-AuNP mixture was incubated with the spheroids
for 2 h. Spheroid viability was analyzed at different time points
(day 4, day 7, and day 10) after the treatment with the ERα-
AuNP or ERα + HER2-AuNP mixture. Results showed that
the nanotags did not appear to have a toxic effect on the
spheroids over the culture period (Figure 1B−D).
Targeting Effect of ERα-AuNP Nanotags in MCF-7
Spheroids: 2D SERS Imaging. To determine the targeting
effect of ERα-AuNPs in ERα-positive MCF-7 breast cancer
spheroids, the spheroids were incubated with either the
targeted ERα-AuNPs or with the nontargeted HER2-AuNPs.
ERα-AuNP nanotags were labeled with a BPE Raman reporter,
and HER2-AuNP nanotags were labeled with a PPY Raman
reporter. Therefore, the targeted ERα-AuNP and the non-
targeted HER2-AuNP nanotags had different reporters on their
surface giving unique identificatory SERS signals. The
concentrations of the reporters were balanced during the
functionalization processes for ERα-AuNP and HER2-AuNP
nanotags. This led to the nanotags having similar Raman
intensities and, therefore, the same signal intensity per
nanoparticle (Figure S3A). This normalization of the intensity
per particle allowed the comparison in SERS intensity of the
targeted and nontargeted nanoparticles. Before their addition
to the spheroids, the ERα-AuNP (BPE Raman reporter) and
HER2-AuNP (PPY Raman reporter) mixture in H2O was
analyzed using SERS. Based on these SERS spectra, 1635 and
955 cm−1 were selected as representative peaks for ERα-
AuNPs (BPE Raman reporter) and HER2-AuNPs (PPY
Raman reporter), respectively (Figure S3B). The spectra
from the two reporters confirmed that they have unique peaks
to identify the ERα-AuNP and HER2-AuNP locations and
targeting when both were present in the spheroids.
Prior to SERS analysis, the empty microfluidic devices were
characterized to confirm that there was no overlapping signal
between the devices and the SERS peaks from BPE and PPY
Raman reporters (Figure S4). At day 4, ERα-AuNPs (60 pM, 2
h) or HER2-AuNPs (60 pM, 2 h) were injected into the
microfluidic devices and incubated for 2 h before washing
twice with PBS to remove any unbound nanotags. Previous
work from our group has shown that 60 pM is an effective
concentration to produce a high SERS response per cell
without affecting the viability of MCF-7 cells.50 2D SERS
mapping from spheroids incubated with ERα-AuNPs demon-
strated a high nanotag accumulation and a strong SERS signal,
confirming the strong targeting effect of the ERα-AuNP
nanotags to the MCF-7 spheroids (Figure 2A,C). In contrast,
the spheroids treated with the nontargeted HER2-AuNP
nanotags appeared to have a lower nanotag accumulation,
demonstrated by the lower SERS signal corresponding to the
PPY Raman reporter on HER2-AuNP nanotags (Figure 2B,C).
These results confirmed that ERα-AuNP targeting was more
effective in the spheroid tumors due to their overexpression of
ERα. Since both the ERα-AuNP nanotags and the HER2-
AuNP nanotags had the same SERS intensity, it is indicated
Figure 2. ERα-AuNP nanotags showed a strong targeting effect toward MCF-7 spheroids, while low HER2-AuNP accumulation was observed in
MCF-7 spheroids due to nonspecific binding. (A) Bright-field image of an MCF-7 spheroid in a microfluidic channel merged with the
corresponding SERS signal from ERα-AuNP nanotags. (B) Bright-field image of an MCF-7 spheroid in a microfluidic channel merged with the
corresponding SERS signal from HER2-AuNP nanotags. (C) Representative SERS spectra from the highest signal points of ERα-AuNPs (red) and
HER2-AuNPs (purple) in MCF-7 spheroids. The devices were turned upside down to facilitate interfacing with the Raman microscope, and the
spheroids were then Raman-imaged using a laser excitation wavelength of 633 nm. 2D SERS mapping was carried out by focusing the laser of a
Renishaw InVia Raman confocal microscope through the depth of the spheroids in the microwells in the microfluidic device. The minimum and
maximum look up table (LUT) thresholds were set to exclude any poorly correlating or noisy spectra (min = 0.6, max = 1).
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that the lower HER2-AuNP accumulation in the MCF-7
spheroids was likely due to their low nonspecific binding in the
spheroids.
The multiplexing capability of SERS was also used to
monitor the uptake of the two types of nanotags in the same
analysis system under the same conditions and to confirm the
specificity of ERα-AuNP nanotags for the MCF-7 spheroids.
Hence, a 1:1 mixture of both the ERα-AuNP and HER2-AuNP
nanotags were co-incubated with the spheroids. The results
from the incubation of the targeted and nontargeted nanotag
mixture in the spheroids confirmed that ERα-AuNP nanotags
had a stronger targeting effect toward MCF-7 spheroids than
HER2-AuNPs. Specifically, the ERα-AuNPs showed greater
accumulation than HER2-AuNPs within the same spheroid
(Figure 3A,B). Additionally, the spheroids had a significantly
higher (2.7 times) Raman signal at 1635 cm−1, the
representative peak of the BPE Raman reporter (Figure 3C)
on ERα-AuNPs, than at 955 cm−1, the representative peak of
the PPY Raman reporter (Figure 3D) on HER2-AuNPs
(Figure 3E). Specifically, there was a 63% reduction in the PPY
signal when the nanotags were attached to the spheroids,
which was a 2.7-fold reduction from a 1:1 mixture. This result
was calculated by taking into consideration the intensity of
PPY in a 1:1 mixture (Figure S5A) and divided it by the fold
reduction in signal from the spheroids (Figure S5B). The
outcome from the calculation was then divided with the
intensity of PPY from a 1:1 mixture and multiplied by 100 for
the estimation of the percentage of the PPY intensity change in
the spheroids.
The exact process that was followed for the quantification of
PPY signal reduction is shown in Figure S5C. The
quantification of the intensity ratio change confirmed that
Figure 3. ERα-AuNPs showed a greater targeting effect and specificity for MCF-7 spheroids than HER2-AuNPs. MCF-7 spheroids incubated with
the ERα + HER2-AuNP mixture (60 pM, 2 h) in microfluidic devices. The false color images correspond to the SERS signal from (A) ERα-AuNPs
and (B) HER2-AuNPs within the same spheroid. The minimum and maximum look up table (LUT) thresholds were set to exclude any poorly
correlating or noisy spectra (minimum = 0.6). (C) Reference spectra of ERα-AuNPs (BPE Raman reporter) (red) and (D) HER2-AuNPs (PPY
Raman reporter) (purple) in H2O. The spectrum was collected using 100% laser power with 0.05 s accumulation time. The inset (dashed box)
shows SERS intensity at 1635 cm−1 (red) that was selected as the representative peak for ERα-AuNPs (BPE Raman reporter) and SERS intensity at
955 cm−1 (red) that was selected as the representative peak for HER2-AuNPs (PPY Raman reporter). (E) Average Raman intensities at 1635
(ERα-AuNPs) and 955 cm−1 (HER2-AuNPs). The average of three samples from three independent biological replicates is shown. Error bars
presented as mean ± S.D. * Significant difference (p < 0.05) in Student’s t test.
Figure 4. ERα-AuNP nanotags demonstrated greater accumulation within the MCF-7 spheroids than HER2-AuNPs. (A) Stacked 3D SERS spectra
from ERα-AuNP nanotags generated at different z positions in the spheroid. (B) Stacked 3D SERS spectra from HER2-AuNPs generated at
different z positions in the spheroid. Spheroids were mapped with a total volume of 200 μm3. Z = 0 represents the center of the spheroid.
Analytical Chemistry pubs.acs.org/ac Article
https://doi.org/10.1021/acs.analchem.1c00188
Anal. Chem. XXXX, XXX, XXX−XXX
F
the targeted nanoparticles (ERα-AuNPs) accumulated more in
the spheroids than the nontargeted nanoparticles (HER2-
AuNPs) in the MCF-7 spheroids. In parallel, the ability of
ERα-AuNPs to identify ERα-positive breast cancer spheroids
using SERS was established. These results show promise for
translating this approach to in vivo experiments where
currently nontargeting nanotags54,55 are used.
Targeting Effect of ERα-AuNP Nanotags in MCF-7
Spheroids: 3D SERS Imaging. 3D SERS mapping was also
used to investigate the uptake, surface adherence, and
penetration abilities of AuNP nanotags into the MCF-7
spheroids and whether differences were present between
targeted nanotags (ERα-AuNPs) and nontargeted ones
(HER2-AuNPs). These differences could give an indication
of whether the nanotags were uptaken by the spheroids or
whether they just adhered to the surface of the spheroids.
Therefore, 3D SERS mapping was carried out throughout the
whole volume (with 200 μm diameter, 4188790.2 um3 volume
in total) of MCF-7 spheroids treated with ERα-AuNPs (60
pM, 2 h) (Figure S6A) or HER2-AuNPs (60 pM, 2 h) (Figure
S6B).
The 3D SERS maps were collected using edge Streamline
HR high confocality mode with a 3 μm step size resolution in
the x and y directions and 4 μm between z-stacks. The
representative average z-stacking results showed that there was
a strong SERS signal from the ERα-AuNP nanotags obtained
at depth within the spheroid volume indicating that the
nanotags were targeting ERα (Figure 4A). MCF-7 spheroids
incubated with HER2-AuNPs were also mapped using 3D
SERS. The representative SERS z-stack signal from HER2-
AuNPs showed that although the SERS signal was detected in
the spheroids, it was much lower than that of ERα-AuNPs
(Figure 4B). The increase of PPY and BPE signals suggests
that there were a greater number of nanoparticles present at
these locations within the cells, resulting in higher average
SERS signals at these locations, which is consistent with the
higher uptake of the ERα-AuNP nanoparticles by the
spheroids. These 3D results confirmed the differences between
the spheroids incubated with targeted ERα-AuNPs and the
ones treated with HER2-AuNP nanotags. Additionally, the
data indicate that ERα-AuNPs have greater retention into the
spheroids than HER2-AuNP nanotags. However, future work
comparing 3D SERS imaging in spheroids with other
techniques, such as immunohistochemistry and transmission
electron microscopy, should be conducted to investigate the
penetration and retention capabilities of the nanotags. These
preliminary studies indicate that HER2-AuNPs demonstrated
much lower accumulation suggesting that their nontargeted
uptake was nonspecific since there was no HER2 for them to
target. The maximum SERS signal for each z-plane established
the ability of the ERα-AuNPs to target ERα and implied the
penetration of the nanotags in the breast cancer spheroids
(Figure S7A,B). Therefore, microfluidics and SERS could
potentially be utilized for the identification and character-
ization of breast cancer tumors ex vivo rapidly with sensitivity
and specificity. The results reported here suggest that targeted
nanoparticles result in higher nanoparticle uptake into
spheroids and potentially tumors than nontargeted, nonspecific
nanoparticle uptake. Therefore, this work shows how function-
alized nanomaterials can be used in the future to characterize
tumor areas by multiplexing the nanotags.
Assessment of Fulvestrant Activity in MCF-7 Sphe-
roids. To further investigate the utility and benefits of the
platform, the effect of nanoparticle uptake after drug treatment
was investigated. Most patients with ERα-positive breast
cancer benefit from endocrine therapy that targets the ERα
pathway with higher efficacy and lower side effects.56
Endocrine therapy involves a class of drugs called selective
estrogen receptor down-regulators (SERDs), which bind to
ERα resulting in its degradation and downregulation.57
Fulvestrant is the first approved SERD for the treatment of
ERα-positive breast cancer.58,59 Previous work from our lab
has shown that MCF-7 cells treated with fulvestrant produced
weaker SERS signals and lower accumulation of nanotags
targeting the ERα receptor, indicating ERα degradation.60
Here, SERS and microfluidics were used to assess the efficacy
of fulvestrant in spheroids. On day 3 of culture, fulvestrant (1
and 10 μM) was added to the spheroids for 24 h. Bright-field
imaging was performed before and after fulvestrant addition to
investigate any induced toxicity and structural differences in
the spheroids (Figure S8A). The results showed that no
significant difference in viability was produced on day 4
(Figure S8B,C). However, a significant reduction in the growth
and increase in the disaggregation of the spheroids treated with
1 and 10 μM fulvestrant compared to the controls were
observed on day 10 (Figure S8D). These results demonstrated
that fulvestrant treatment increased the number of dead cells in
the cancer spheroid model over time confirming its toxic effect.
Therefore, day 4 was chosen as an optimal time point to assess
the nanotag targeting effect based on the SERS response after
24 h of fulvestrant treatment. The spheroids were incubated on
day 4 with ERα-AuNPs (60 pM, 2 h) and washed twice with
PBS after 2 h to remove any unbound nanotags. SERS imaging
was then carried out using a laser excitation wavelength of 633
nm (Figure S9). For SERS mapping, similarly sized spheroids
were chosen from both the untreated and fulvestrant-treated
samples. This step was carried out to increase the confidence
that any eventual reduction of the SERS signal in the
fulvestrant-treated spheroids was due to the ERα degradation
and not due to spheroid size. SERS mapping showed that there
was lower nanotag accumulation in the spheroids treated with
10 μM fulvestrant than with 1 μM fulvestrant and the
untreated spheroids (Figure 5A).
Additionally, a statistically significant decrease (1.8 times)
was observed in the SERS intensity at 1635 cm−1
(representative peak of the BPE Raman reporter attached to
the ERα-AuNPs) after treatment with 10 μM of fulvestrant
compared to the untreated spheroids (Figure 5B). These
results confirmed that ERα degradation had occurred due to
the fulvestrant treatment and validated that the targeting of
ERα-AuNP nanotags toward ERα could be used to monitor
the expression level in response to drug treatment. This is a
significant first step in demonstrating the potential of using
SERS and 3D cultures as a tool for preclinical drug validation.
This has potential benefits in terms of the reduction in animal
use for drug screening as only the most promising targets
would be taken forward for in vivo experiments and ultimately
increases positive outcomes and benefits patients through
better informed treatment decision-making.
■ CONCLUSIONS
Metal nanoparticles are commonly used in cancer as drug
delivery,61,62 photothermal,63,64 and imaging agents.65−67 Here,
we demonstrate that the multiplexing capabilities of SERS
combined with targeted anti-ERα antibody-functionalized
(ERα-AuNPs) and nontargeted anti-HER2 antibody-function-
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alized (HER2-AuNPs) nanotags can be successfully used to
understand more about nanoparticle uptake in tumor
spheroids with the advantages of high sensitivity and
specificity. The results showed that SERS can provide a
sensitive method for the analysis of 3D tumor models grown in
microfluidic chips. Specifically, the combination of 3D
spheroids and SERS was successfully applied to identify and
classify live ERα-positive MCF-7 breast cancer spheroids and
to compare the uptake of targeted and nontargeted nano-
particles into the 3D tumor model. The spheroids formed in
the microfluidic device maintained their integrity and viability
after SERS nanotag treatment, offering a versatile and robust
methodology for scalable and multistep assays. A strong
targeting effect of ERα-AuNPs was observed in MCF-7
spheroids compared to HER2-AuNPs. 3D SERS mapping
revealed that the SERS signal was detected from areas within
the inner part of the spheroid, suggesting the uptake and
penetration of the nanotags into the spheroid. Furthermore,
SERS allowed the assessment of fulvestrant activity on ERα
expression levels post treatment. Specifically, the reduction of
ERα protein after fulvestrant treatment was confirmed from
the lower SERS signal in the fulvestrant-treated spheroids.
Several studies have reported similar drug behaviors in
2D,68−71 which support our data in a 3D environment. This
work highlights the importance of performing assays on 3D
cultures that reflect better the tissue architecture and the cell-
to-cell and cell-to-matrix interactions making them a great
model to predict the drug responses in vivo. Future
opportunities may involve multiplexed detection of biomarkers
and investigation of the drug activity in patient-derived
spheroids for extensive characterization of tumor tissue and
its response to treatment.
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Renishaw InVia microspectrometer and direct classical least squares
analysis (DCLS) based on a BPE Raman reporter reference spectrum.
The minimum and maximum look up table (LUT) thresholds were
set to exclude any poorly correlating or noisy spectra (min = 0.6, max
= 1). (B) Average Raman intensity at 1635 cm−1 (representative peak
for the BPE Raman reporter on ERα-AuNPs). The average of three
samples is shown. Error bars presented as mean ± S.D. * Significant
difference (p < 0.05) in a one-way analysis of variance (ANOVA) test.
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